Which pain block works better for breast surgery?
NCT ID NCT07807605
First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time
Summary
This trial compares two ultrasound-guided pain relief techniques for women undergoing breast-conserving surgery for cancer: a serratus anterior plane block and a thoracic epidural. Both use the local anesthetic bupivacaine to numb nerves and reduce post-operative pain. The study will measure pain levels at several time points after surgery and see how long each block provides effective relief. The goal is to find which method offers better pain control with fewer side effects.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Bupivacaine 0.25% injectable solution, used in two different nerve block techniques: serratus anterior plane block and thoracic epidural analgesia
- What this could lead to
- If one method proves better, it could offer women undergoing breast-conserving surgery a more effective and safer way to manage post-operative pain, potentially reducing opioid use and speeding recovery.
- What could go wrong
- This is a small, single-center study, and results may not apply to all patients. Both techniques carry risks like infection, bleeding, or nerve damage, and individual responses to pain relief can vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
70 people
The number who actually took part.
- Started
-
Jan 2023
- Finished
-
Jun 2023
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
20 to 60 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * patients of the American Society of Anesthesiology physical status (І and ІІ) Female patients. * Female patients diagnosed with breast malignancy * Patients with Body weight: patients with body mass index less than 35. Exclusion Criteria: * Uncooperative patient, those with any contraindication for spinal or epidural anesthesia (systemic coagulopathy-local infection) * Patients with body mass index \>35 * Patients with chronic obstructive pulmonary disease * Patients with anatomic abnormalities * Patients with allergy to study drugs
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beni Suef University Hospital
Banī Suwayf, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Retrospective analysis of pyrotinib in the treatment of HER2-Positive advanced breast cancer previously treated with trastuzumab and pertuzumab
- Mind and body: does resilience leave a molecular mark in breast cancer?
- Can a Triple-Drug combo erase HER2-Positive breast tumors before surgery?
- Bacteria inside tumors may hold the key to breast cancer treatment
- Can a newer drug ease the bone pain of chemotherapy support?
- Can a new drug shrink tumors that resist standard care?